RSK and CHK2 Inhibitors for Diamond Blackfan Anemia Rescue

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatment options for ribosomal disorders and ribosomopathies, such as Diamond Blackfan anemia (DBA), are not optimal, particularly for small-molecule drug therapies.

Innovation Solution

The use of inhibitors of RSK (p90S6K), p70S6K, Rps6, Chk2, and specific phenothiazine derivatives like ACV, 221E, PerSucc, DB-4-088-2, DB-4-088-3, DB-4-086, DB-4-087-2, and DB-4-089 to target RSK signaling and p53 activity in ribosomal protein deficient cells, thereby increasing hemoglobin and rescuing morphological and hematopoietic defects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment options are used for ribosomal disorders, then treatment is provided, but treatment effectiveness is not optimal

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment suitability for ribosomal disorders

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from general supportive care to targeted inhibition of specific molecular pathways (RSK, p70S6K, Chk2, p53). This parameter change enables effective treatment of ribosomal disorders by modulating the activity of these kinases and transcription factors, thereby improving treatment effectiveness and suitability for this specific disease class

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If inhibitors of RSK, p70S6K, Chk2 and phenothiazine derivatives are used, then hemoglobin levels increase and erythroid differentiation improves, but p53 activity is reduced

Engineering Contradiction:

Improvehemoglobin levelsVSAvoidp53 activity

Core Design Contradiction:

Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of elevated p53 activity (which causes cell cycle arrest and apoptosis in ribosomal protein-deficient cells) into a beneficial therapeutic outcome by using inhibitors to suppress p53. This suppression of p53 activity, initially a harmful factor, becomes the mechanism that rescues erythroid differentiation and increases hemoglobin production in DBA patients

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12569486B2Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies

Publication Date: 2026.03.10 DANA FARBER CANCER INSTITUTE INC

AI summary

The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.